Trial · NCT07896746
Factors Influencing Adoption of a Novel Malaria Treatment in Côte d'Ivoire, Ghana, and Rwanda
NCT07896746, Not yet recruiting, Novartis Pharmaceuticals
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Factors Influencing Adoption of a Novel Malaria Treatment in Côte d'Ivoire, Ghana, and Rwanda. Trials, record NCT07896746. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07896746
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Factors Influencing Adoption of a Novel Malaria Treatment in Côte d'Ivoire, Ghana, and Rwanda
- NCT number
- NCT07896746
- Status
- Not yet recruiting
- Enrollment
- 184 participants, estimated
- Lead sponsor
- Novartis Pharmaceuticals
- Conditions
- Malaria
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Multilevel Barriers and Facilitators Influencing Adoption of a Novel Malaria Treatment | At the one-time interview, lasting approximately 75 minutes | Individual-, community-, healthcare-provider-, health-system-, and policy-level barriers and facilitators influencing the anticipated adoption of a novel malaria treatment will be identified through thematic analysis of one-time, semi-structured, in-depth interviews with patients, caregivers, healthcare providers, pharmacists, other antimalarial dispensers, and community health personnel. Findings will be organized using the Consolidated Framework for Implementation Research and the Capability, Opportunity, Motivation-Behavior model. |
| Secondary | Barriers and Facilitators Affecting Treatment-Seeking Behavior | At the one-time interview, lasting approximately 75 minutes. | Barriers and facilitators affecting recognition of malaria symptoms, decisions to seek care, selection of treatment sources, treatment access, and delays in obtaining care will be identified through thematic analysis of participant interviews. |
| Secondary | Factors Affecting Acceptability of a Novel Malaria Treatment | At the one-time interview, lasting approximately 75 minutes. | Participant perceptions of the acceptability of a novel powder-in-sachet malaria treatment will be assessed through interview discussions addressing formulation, dosing schedule, preparation, administration, taste, packaging, instructions, storage, and suitability across patient groups and care settings. |
| Secondary | Barriers and Facilitators Affecting Malaria Treatment Adherence | At the one-time interview, lasting approximately 75 minutes. | Patient-, caregiver-, provider-, community-, and health-system-related factors that may influence correct treatment preparation, dosing, persistence, and completion of malaria treatment will be identified through thematic analysis of participant interviews. |
| Secondary | Factors Affecting Provider Prescribing and Treatment-Support Practices | At the one-time interview, lasting approximately 75 minutes. | Factors influencing healthcare-provider and community-health-worker diagnosis, prescribing, dispensing, treatment administration, counselling, and adherence-support practices for uncomplicated malaria will be identified through thematic analysis of interviews. |
| Secondary | Implementation Options to Support Adoption of a Novel Malaria Treatment | At the one-time interview, lasting approximately 75 minutes. | Stakeholder-informed implementation options will be identified from interview data, including potential approaches related to training, communication, patient instructions, treatment preparation, supply and distribution, health-system readiness, and community support. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07896746
GET https://conductscience.org/api/trials/v1/NCT07896746/registered